ATE262525T1 - Indolderivate zur verwendung in der behandlung von zns-störungen - Google Patents

Indolderivate zur verwendung in der behandlung von zns-störungen

Info

Publication number
ATE262525T1
ATE262525T1 AT01940242T AT01940242T ATE262525T1 AT E262525 T1 ATE262525 T1 AT E262525T1 AT 01940242 T AT01940242 T AT 01940242T AT 01940242 T AT01940242 T AT 01940242T AT E262525 T1 ATE262525 T1 AT E262525T1
Authority
AT
Austria
Prior art keywords
treatment
cns disorders
indole derivatives
indole
derivatives
Prior art date
Application number
AT01940242T
Other languages
English (en)
Inventor
Benny Bang-Andersen
Krestian Larsen
Jan Kehler
Original Assignee
Lundbeck & Co As H
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Lundbeck & Co As H filed Critical Lundbeck & Co As H
Application granted granted Critical
Publication of ATE262525T1 publication Critical patent/ATE262525T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/26—Psychostimulants, e.g. nicotine, cocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Neurosurgery (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biomedical Technology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Neurology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Psychiatry (AREA)
  • Pain & Pain Management (AREA)
  • Psychology (AREA)
  • Anesthesiology (AREA)
  • Hospice & Palliative Care (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
AT01940242T 2000-06-19 2001-06-13 Indolderivate zur verwendung in der behandlung von zns-störungen ATE262525T1 (de)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
DKPA200000957 2000-06-19
US21253200P 2000-06-20 2000-06-20
PCT/DK2001/000408 WO2001098298A1 (en) 2000-06-19 2001-06-13 Indole derivatives useful for the treatment of cns disorders

Publications (1)

Publication Number Publication Date
ATE262525T1 true ATE262525T1 (de) 2004-04-15

Family

ID=26068837

Family Applications (1)

Application Number Title Priority Date Filing Date
AT01940242T ATE262525T1 (de) 2000-06-19 2001-06-13 Indolderivate zur verwendung in der behandlung von zns-störungen

Country Status (14)

Country Link
EP (1) EP1299384B1 (de)
JP (1) JP2004501151A (de)
KR (1) KR20030007975A (de)
CN (1) CN1446216A (de)
AR (1) AR028945A1 (de)
AT (1) ATE262525T1 (de)
AU (1) AU2001273883A1 (de)
CA (1) CA2412141A1 (de)
CZ (1) CZ200357A3 (de)
DE (1) DE60102471T2 (de)
HU (1) HUP0301748A2 (de)
MX (1) MXPA02012568A (de)
NO (1) NO20026028D0 (de)
WO (1) WO2001098298A1 (de)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PL1708790T3 (pl) 2003-12-02 2010-10-29 Pharmaneuroboost N V Zastosowanie pipamperonu oraz antagonisty receptora D2 lub antagonisty receptora serotoniny/dopaminy do leczenia zaburzeń psychotycznych
EP1547650A1 (de) * 2003-12-02 2005-06-29 B & B Beheer NV Verwendung von D4 und 5-HT2A Antagonisten, inverse Agonisten order partielle Agonisten
US7855195B2 (en) 2003-12-02 2010-12-21 Pharmaneuroboost N.V. Method of treating mental disorders using D4 and 5-HT2A antagonists, inverse agonists or partial agonists
US7884096B2 (en) 2003-12-02 2011-02-08 Pharmaneuroboost N.V. Method of treating mental disorders using of D4 and 5-HT2A antagonists, inverse agonists or partial agonists

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BR9406128A (pt) * 1993-03-01 1996-02-27 Merck Sharp & Dohme Uso de um composto processo para o tratamento e/ou prevençao de distúrbios psicóticos composto composiçao farmacêutica processos para a preparaçao de um composto e de uma composiçao farmacêutica
DE19500689A1 (de) * 1995-01-12 1996-07-18 Merck Patent Gmbh Indolpiperidin-Derivate
GB9700895D0 (en) * 1997-01-17 1997-03-05 Lilly Co Eli Pharmaceutical compounds

Also Published As

Publication number Publication date
DE60102471D1 (de) 2004-04-29
CA2412141A1 (en) 2001-12-27
AR028945A1 (es) 2003-05-28
JP2004501151A (ja) 2004-01-15
EP1299384A1 (de) 2003-04-09
KR20030007975A (ko) 2003-01-23
CN1446216A (zh) 2003-10-01
EP1299384B1 (de) 2004-03-24
CZ200357A3 (cs) 2003-04-16
HUP0301748A2 (hu) 2003-09-29
NO20026028L (no) 2002-12-16
DE60102471T2 (de) 2005-02-24
NO20026028D0 (no) 2002-12-16
WO2001098298A1 (en) 2001-12-27
AU2001273883A1 (en) 2002-01-02
MXPA02012568A (es) 2003-04-10

Similar Documents

Publication Publication Date Title
ATE269303T1 (de) Arylpiperazinyl-cyclohexyl indolderivate zur behandlung von depressionen
DE60019556D1 (de) 2-amino-benzoxazinonderivate zur behandlung von fettleibigkeit
DE69936335D1 (de) Verwendung von morpholinol zur behandlung von sexuellen funktionsstörungen
DE60124302D1 (de) Thiazolderivate zur behandlung von ppar-lierte krankheiten
DE69925571D1 (de) Sulphonamid-derivate zur behandlung von störungen des zentralnervensystems
DE60019555D1 (de) 2-oxy-benzoxazinonderivate zur behandlung von fettleibigkeit
DE60022867D1 (de) 1-Arenesulfonyl-2-Aryl-Pyrrolidin und Piperidin Derivative zur Behandlung von CNS-Erkrankungen
DE60136477D1 (de) Retinoide zur behandlung von emphysem
ATE297391T1 (de) Indolderivate zum gebrauch in der behandlung von zns-störungen
DE60117122D1 (de) Verwendung von mirtazapin zur behandlung von schlafstörungen
ATE230741T1 (de) 3-tetrahydropyridin-4-yl-indole zur behandlung von psychotischen störungen
ATE262525T1 (de) Indolderivate zur verwendung in der behandlung von zns-störungen
DE60217653D1 (de) Verwendung von melatonin zur behandlung der mit konzentrationsschwäche einhergehenden hyperaktivität
DE60103761D1 (de) Indolderivate zum gebrauch in der behandlung von zns-störungen
DE69918541D1 (de) Verwendung von nmda antagonisten zur behandlung des reizkolons
NO20030127D0 (no) Indolderivater nyttige for behandling av CNS-forstyrrelser
DE60005685D1 (de) Oxazinocarbazole zur behandlung von cns-erkrankungen
ATE300531T1 (de) Isonipecotamide zur behandlung von integrin vermittelten störungen
DE60124791D1 (de) S-Methyl-Dihydro-Ziprasidone zur Behandlung von psychiatrischen Störungen.
DE59904564D1 (de) Verwendung von acetylcholinesterase-inhibitoren zur behandlung von delirien
ATE344671T1 (de) Verwendung von enoxaparin zur behandlung der zerebralen ischämie
HK1059086A1 (en) Indole derivatives useful for the treatment of cns disorders
IL153351A0 (en) Indole derivatives useful for the treatment of cns disorders
SI1294710T1 (en) Indole derivatives useful for the treatment of cns disorders

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties